Ramipril Findings Draw Spotlight
A group of investigators has found that the ACE inhibitor ramipril (Hoechst Marion Roussel’s Altace) significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or heart failure.
Because of the potential therapeutic implications of those findings, the New England Journal of Medicine released a preliminary report on the study in November via the Internet in advance of its planned publication date. The preliminary report can be found at www.nejm.org/content/yusuf/1.asp.
The Heart Outcomes Prevention Evaluation Study Investigators’ article, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients" will be published in the Jan. 20, 2000, New England Journal of Medicine.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content